ResMed Inc. (NYSE:RMD) Shares Purchased by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC boosted its holdings in ResMed Inc. (NYSE:RMD) by 4.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,558 shares of the medical equipment provider’s stock after purchasing an additional 100 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in ResMed were worth $624,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its holdings in shares of ResMed by 51.4% in the second quarter. Bank of New York Mellon Corp now owns 5,772,761 shares of the medical equipment provider’s stock valued at $1,105,022,000 after acquiring an additional 1,959,642 shares during the period. Marshall Wace LLP acquired a new stake in shares of ResMed in the second quarter valued at approximately $77,285,000. Greenvale Capital LLP boosted its holdings in shares of ResMed by 61.1% in the second quarter. Greenvale Capital LLP now owns 725,000 shares of the medical equipment provider’s stock valued at $138,780,000 after acquiring an additional 275,000 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of ResMed by 48.3% during the second quarter. Los Angeles Capital Management LLC now owns 740,226 shares of the medical equipment provider’s stock worth $141,694,000 after purchasing an additional 241,195 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of ResMed during the second quarter worth $42,036,000. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed Trading Up 1.4 %

ResMed stock opened at $241.55 on Thursday. The stock has a market cap of $35.46 billion, a PE ratio of 31.99, a P/E/G ratio of 1.71 and a beta of 0.69. The stock has a 50-day moving average price of $242.10 and a 200 day moving average price of $224.10. ResMed Inc. has a 52 week low of $150.39 and a 52 week high of $260.49. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. Equities research analysts predict that ResMed Inc. will post 9.28 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed’s dividend payout ratio is presently 28.08%.

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brett Sandercock sold 1,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $246.42, for a total value of $246,420.00. Following the completion of the sale, the chief financial officer now directly owns 96,812 shares in the company, valued at approximately $23,856,413.04. The trade was a 1.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,174 shares of company stock valued at $14,882,278. Insiders own 0.71% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on RMD. Baird R W raised ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Friday, October 25th. Robert W. Baird increased their price target on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Royal Bank of Canada increased their price target on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $225.70.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.